| 2.08 -0.09 (-4.15%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.72 |
1-year : | 3.33 |
| Resists | First : | 2.32 |
Second : | 2.85 |
| Pivot price | 2.16  |
|||
| Supports | First : | 1.48 |
Second : | 1.23 |
| MAs | MA(5) : | 2.37 |
MA(20) : | 2.09 |
| MA(100) : | 1.9 |
MA(250) : | 1.4 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 39 |
D(3) : | 62 |
| RSI | RSI(14): 49.2 |
|||
| 52-week | High : | 2.85 | Low : | 0.52 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ PALI ] has closed above bottom band by 41.8%. Bollinger Bands are 77.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.19 - 2.21 | 2.21 - 2.22 |
| Low: | 2 - 2.02 | 2.02 - 2.03 |
| Close: | 2.06 - 2.08 | 2.08 - 2.1 |
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.
Sat, 25 Apr 2026
Here's Why Palisade Bio (PALI) Could be Great Choice for a Bottom Fisher - MSN
Tue, 21 Apr 2026
Analysts Offer Predictions for Palisade Bio Q1 Earnings - MarketBeat
Fri, 17 Apr 2026
Wolfe Highlights Differentiation Potential in Palisade Bio, Inc. (PALI) Clinical Profile - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 167 (M) |
| Shares Float | 123 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 81.6 (%) |
| Shares Short | 25,770 (K) |
| Shares Short P.Month | 26,730 (K) |
| EPS | -0.31 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.81 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -15.6 % |
| Return on Equity (ttm) | -24.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.11 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -11 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -6.94 |
| PEG Ratio | 0 |
| Price to Book value | 2.56 |
| Price to Sales | 0 |
| Price to Cash Flow | -32.1 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|